NEITHER A COX-2 INHIBITOR NOR NSAID PLUS PPI ADEQUATELY PROTECTED HIGH RISK PATIENTS FROM PEPTIC ULCER RECURRENCE

2005 ◽  
Vol 6 (1) ◽  
pp. 11-12
Author(s):  
Richard J Saad ◽  
James M Scheiman
2003 ◽  
Vol 124 (4) ◽  
pp. A239 ◽  
Author(s):  
Marc Bardou ◽  
Youssef M. Toubouti ◽  
Dalila Benhaberou-Brun ◽  
Elham Rhame ◽  
Alan N. Barkun

1987 ◽  
Vol 11 (3) ◽  
pp. 345-349 ◽  
Author(s):  
Bruce E. Stabile ◽  
Chang Tzu-Ming ◽  
Jonathan R. Hiatt ◽  
Edward Passaro

Diabetes Care ◽  
2006 ◽  
Vol 30 (1) ◽  
pp. 14-20 ◽  
Author(s):  
L. A. Lavery ◽  
K. R. Higgins ◽  
D. R. Lanctot ◽  
G. P. Constantinides ◽  
R. G. Zamorano ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A104 ◽  
Author(s):  
Kam-Chuen Lai ◽  
Kent-Man Chu ◽  
Wai-Mo Hui ◽  
Chun-Yu Wong ◽  
Wayne Hu ◽  
...  

2003 ◽  
Vol 37 (11) ◽  
pp. 1664-1674 ◽  
Author(s):  
Jill M Herendeen ◽  
Celeste Lindley

OBJECTIVE: To discuss the role of nonsteroidal antiinflammatory drugs (NSAIDs) in the chemoprevention of colorectal cancer. DATA SOURCES: A MEDLINE search (1966–May 2003) was performed to identify key literature. Search items included, but were not limited to, NSAIDs, colorectal cancer, chemoprevention, cyclooxygenase-2 (COX-2)–specific inhibitors, and familial adenomatous polyposis (FAP). STUDY SELECTION AND DATA EXTRACTION: The search included experimental (in vitro and animal models) and clinical studies evaluating the use of NSAIDs for the chemoprevention of colorectal cancer. The MEDLINE search was supplemented by references from selected articles. DATA SYNTHESIS: Numerous experimental, epidemiologic, and clinical studies suggest that NSAIDs have promise as anticancer agents. The mechanism by which NSAIDs lead to decreased colon carcinogenesis is not fully understood, but may involve restoration of apoptosis and inhibition of prostaglandin-mediated angiogenesis. Compelling evidence from many observational studies has consistently documented a 40–50% reduction in the risk of adenomatous polyps, colorectal cancer incidence, and mortality in patients using NSAIDs. Recent randomized, controlled trials have demonstrated a benefit with aspirin in reducing the rate of development of new or recurrent adenomas in high-risk patients. In addition, randomized studies using sulindac and celecoxib in patients with FAP have documented significant regression of existing adenomatous polyps. CONCLUSIONS: Inhibition of COX-2 is an example of a targeted approach to the chemoprevention of colorectal cancer. However, controversy exists about the safety, efficacy, and optimal treatment regimen of NSAIDs as long-term chemopreventive agents in the general population. Ongoing studies in high-risk patients with both selective and nonselective COX inhibitors will provide important information in the area of colorectal chemoprevention, but clinical trials' use of adenomas as surrogate markers for chemoprevention trials makes their application to the general population limited.


Sign in / Sign up

Export Citation Format

Share Document